{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:08Z","timestamp":1787016908261,"version":"build-2736575974"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"crossref","award":["HHSO100201900007C"],"award-info":[{"award-number":["HHSO100201900007C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["BX002872"],"award-info":[{"award-number":["BX002872"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,11,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Taniborbactam (formerly VNRX-5133) is a novel, investigational boronic acid \u03b2-lactamase inhibitor. The combination of cefepime (FEP) with taniborbactam is active against\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      carrying class A, B, C, and\/or D enzymes. We assessed the activity of FEP-taniborbactam against\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      clinical strains carrying\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA-48<\/jats:sub>\n                      (\n                      <jats:italic>N<\/jats:italic>\n                      = 50, 100%), of which 78% harbored at least one extended-spectrum \u03b2-lactamase (ESBL). CLSI-based agar dilution susceptibility testing was conducted using FEP-taniborbactam and comparators FEP, meropenem-vaborbactam (MVB), and ceftazidime-avibactam (CZA). The addition of taniborbactam lowered FEP MICs to the provisionally susceptible range of \u226416 \u00b5g\/mL; the MIC\n                      <jats:sub>90<\/jats:sub>\n                      value decreased from \u226564 \u00b5g\/mL for FEP to 4 \u00b5g\/mL for FEP-taniborbactam. Notably, FEP-taniborbactam MIC\n                      <jats:sub>50<\/jats:sub>\n                      \/MIC\n                      <jats:sub>90<\/jats:sub>\n                      values (0.5\/4 \u00b5g\/mL) were lower than those for MVB (1\/16 \u00b5g\/mL) and comparable to those for CZA (0.5\/1 \u00b5g\/mL). Time-kill assays with\n                      <jats:italic>E. coli<\/jats:italic>\n                      clinical strains DOV (\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA-48<\/jats:sub>\n                      ,\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>CTX-M-15<\/jats:sub>\n                      ,\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>TEM-1<\/jats:sub>\n                      , and\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA-1<\/jats:sub>\n                      ) and MLI (\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA-48<\/jats:sub>\n                      ,\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>VEB<\/jats:sub>\n                      ,\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>TEM-1<\/jats:sub>\n                      , and\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>CMY-2<\/jats:sub>\n                      ) revealed that FEP-taniborbactam at concentrations 1\u00d7, 2\u00d7, and 4\u00d7 MIC displayed time-dependent reductions in the number of CFU\/mL from 0 to 6 h, and at 4\u00d7 MIC demonstrated bactericidal activity (3 log\n                      <jats:sub>10<\/jats:sub>\n                      reduction in CFU\/mL at 24 h). Therefore, taniborbactam in combination with FEP was highly active against this diverse panel of\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      with\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA-48<\/jats:sub>\n                      and represents a potential addition to our antibiotic arsenal.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        OXA-48-like \u03b2-lactamases are class D carbapenemases widespread in\n                        <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                        and other\n                        <jats:italic>Enterobacterales<\/jats:italic>\n                        and are associated with carbapenem treatment failures. As up to 80% of OXA-48-like positive isolates coproduce extended-spectrum \u03b2-lactamases, a combination of \u03b2-lactams with broad-spectrum \u03b2-lactamase inhibitors is required to counteract all OXA-48-producing strains effectively. Herein, we evaluated the activity of cefepime-taniborbactam against 50 clinical strains producing OXA-48. We report that adding taniborbactam shifted the minimum inhibitory concentration (MIC) toward cefepime\u2019s susceptible range, restoring its antimicrobial activity. Notably, cefepime-taniborbactam MIC\n                        <jats:sub>50<\/jats:sub>\n                        \/MIC\n                        <jats:sub>90<\/jats:sub>\n                        values (0.5\/4 \u00b5g\/mL) were comparable to ceftazidime-avibactam (0.5\/1 \u00b5g\/mL). Finally, time-kill assays revealed sustained bactericidal activity of cefepime-taniborbactam for up to 24 h. In conclusion, cefepime-taniborbactam will be a welcome addition to the antibiotic arsenal to combat\n                        <jats:italic>Enterobacterales<\/jats:italic>\n                        producing OXA-48.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.01144-24","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:03:31Z","timestamp":1727168611000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Cefepime-taniborbactam demonstrates potent\n                    <i>in vitro<\/i>\n                    activity vs\n                    <i>Enterobacterales<\/i>\n                    with\n                    <i>bla<\/i>\n                    <sub>OXA-48<\/sub>"],"prefix":"10.1128","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-9824","authenticated-orcid":true,"given":"Maria F.","family":"Mojica","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA"},{"name":"CASE-VA Center for Antimicrobial Resistance and Epidemiology, Cleveland, Ohio, USA"},{"name":"Grupo de Resistencia Antimicrobiana y Epidemiolog\u00eda Hospitalaria, Universidad El Bosque, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise T.","family":"Zeiser","sequence":"additional","affiliation":[{"name":"Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Becka","sequence":"additional","affiliation":[{"name":"Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-1711","authenticated-orcid":false,"given":"David A.","family":"Six","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-7227","authenticated-orcid":true,"given":"Greg","family":"Moeck","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-7898","authenticated-orcid":true,"given":"Krisztina M.","family":"Papp-Wallace","sequence":"additional","affiliation":[{"name":"Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)93393-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku524"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks121"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10020258"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.5b00298"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00798"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.12.006"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.15-22.2004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab306"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01518"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00911"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01963-19"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01281-22"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa391"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa053"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02338-20"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106440"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00069-5"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00991-23"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab197"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02179-21"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21"},{"key":"e_1_3_3_32_2","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases","author":"Weiss W","year":"2018","unstructured":"Weiss W, Pulse M, Nguyen P, Valtierra D, Peterson K, Carter K, Pevear D, Burns CR, Xerri L. 2018. O0600: efficacy of cefepime\/VNRX-5133, a novel b-lactamase inhibitor, against cephalosporin-resistant, ESBL-producing K. pneumoniae in a murine lung-infection model. European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain"},{"key":"e_1_3_3_33_2","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases","author":"Weiss W","year":"2018","unstructured":"Weiss W, Pulse M, Nguyen P, Valtierra D, Pevear D, Burns CR, Xerri L. 2018. P1538: efficacy of cefepime\/VNRX-5133, a novel broad-spectrum b-lactamase inhibitor, in a murine bacteraemia infection model with carbapenem-resistant Enterobacteriaceae (CREs). European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa373"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac446"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab405"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304748"},{"key":"e_1_3_3_38_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. CLSI supplement M100. In Performance standards for antimicrobial susceptibility testing, 33rd ed. Clinical and Laboratory Standards Institute Wayne, Pennsylvania, USA.","edition":"33"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab405"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01053-21"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00253-22"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00216-22"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00102-19"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00022-11"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00537-17"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00989-17"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00548-15"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00590-16"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki074"},{"key":"e_1_3_3_53_2","volume-title":"Methods for dilution antimicrobial susceptiblity tests for bacteria that grow aerobically","author":"CLSI","year":"2006","unstructured":"CLSI. 2006. Methods for dilution antimicrobial susceptiblity tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA, USA."},{"key":"e_1_3_3_54_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline","author":"CLSI","year":"1999","unstructured":"CLSI. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA, USA."}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01144-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01144-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:45:04Z","timestamp":1730799904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01144-24"}},"subtitle":[],"editor":[{"given":"Olaya","family":"Rendueles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,5]]}},"alternative-id":["10.1128\/spectrum.01144-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01144-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"2024-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01144-24"}}